The objective of this prospective, observational study was to define the natural history of neutropenia in human immunodeficiency virus (HIV) disease. Eighty-seven consecutive patients developing neutropenia (absolute neutrophil count [ANC], !1000 cells/mm 3 ) were recruited and closely followed for the duration of the episode. Episodes lasted a median of 13 days, with a mean ANC nadir of 660 cells/mm 3 . Presumed or proven infection occurred in 12 (17%) of 71 evaluable subjects, and culture-proven infection occurred only in 6 (8%) of 71. Most of the episodes of neutropenia were brief, mild to moderate in nadir, and self-limiting without complications. Myelosuppressive therapies were implicated in almost all episodes. Serious infections occurred infrequently and were associated with low ANC nadirs but not with duration of the neutropenic episode. Low CD4 + cell counts also increased the risk of infection complicating an episode of neutropenia.
terial infections affecting individuals with HIV infection in our unit occur in patients with neutropenia [6] . The frequency with which neutropenia is complicated by infection is less clear, and the factors associated with both development of neutropenia and particularly episodes of neutropenia that go on to be complicated by infection have not been clearly established. Therefore, a study of the burden of neutropenia in our clinic was undertaken.
The first part of this study was retrospective, the results of which are reported elsewhere [7] . The principal aim of the study reported here was to prospectively observe the natural history of neutropenia in the setting of HIV infection. We sought to define the likely etiology for each episode and attempt to describe those patients most likely to have complicating infection.
PATIENTS AND METHODS
This prospective study was performed from 20 November 1996 through 20 July 1997 at the HIV Inpatient and Outpatient Unit, Kobler Clinic, St. Stephens' Centre, Chelsea and Westminster Hospital (London). The general clinic population includes homosexual or bisexual men (∼80% of patients), injection drug users (7%), and African heterosexuals (3%). Every full blood count determined for unit inpatients and outpatients was screened, and all adult patients with a new episode of neutropenia (defined as an absolute neutrophil count [ANC] of !1000 cells/ mm 3 ) were recruited to the study. Subjects who were already neutropenic at the start of the study and those with no previously recorded ANC of у1000 cells/mm 3 were excluded from the study, because it was considered important to be able to estimate the date of onset for each episode. Patients receiving cytotoxic chemotherapy were also excluded from the study.
Serial ANCs were determined at least weekly (fortnightly after 6 weeks) until the ANC rose to у1000 cells/mm 3 , and all patients were examined regularly by one of the authors (D. A. J. M.) for signs or symptoms of sepsis. All prior ANCs, CD4/ CD8 cell counts, drug therapy, and illnesses were recorded. The duration of an episode of neutropenia was defined as the time from the first ANC of !1000 cells/mm 3 to the next ANC of у1000 cells/mm 3 . The characteristics of subjects having their first episode of neutropenia were compared with those of subjects having a recurrent episode. During the study period, there was a protocol extant for the use of granulocyte colony-stimulating factor (G-CSF) if certain stringent clinical criteria were satisfied. Thus, subjects with a clinical picture highly suggestive of systemic infection (fever, rigors, tachycardia, and hypotension) or signs indicative of a focus of infection received G-CSF therapy if ANCs were !1000 cells/mm 3 . For subjects with suspicious symptomatology but no systemic disorder, close outpatient observation (after obtaining appropriate cultures) was undertaken, and G-CSF treatment was used only if clinical features suggested progression of infection and the ANC was !500 cells/mm 3 . Student's t test and x 2 test were used to compare the characteristics of subjects having a first or recurrent episode.
RESULTS

Etiology.
Of 15,476 outpatient attendances and 534 inpatient episodes, 87 patients had ANCs fulfilling the definition of neutropenia. Ten of these patients were female, consistent with the demographics of the clinic population. The median age of the 87 patients was 38 years. All the potentially myelosuppressive drug therapies received by these patients are detailed in table 1. Only 3 of these patients were not being treated with drugs reportedly associated with neutropenia, and 59 were receiving 3 or more potentially myelosuppressive therapies. Only 12 (14%) of the 87 patients were not being treated with zidovudine, lamivudine, and/or co-trimoxazole. Six patients were receiving treatment with a single drug that has been only rarely reported to be associated with myelosuppression. None of these 6 patients or the 3 who were not receiving treatment with myelosuppressive drugs were receiving any complementary therapies at the time, nor did they have any underlying opportunistic disorder with apparent bone marrow involvement, despite prolonged follow-up.
Only 3 patients in the whole study had opportunistic infections that might have involved the bone marrow (active infection with Mycobacterium avium/Mycobacterium intracellulare, pulmonary tuberculosis, and lymphoma). A further 10 subjects were receiving secondary prophylaxis for M. avium/M. intracellulare infection, but these infections appeared to be under control ( Excluded from this analysis were 16 patients for whom follow-up determination of ANCs was not performed for 121 days (mean delay, 49 days; range, 22-96 days). Because followup ANCs were normal for 13 of these 16 patients, durations of these episodes of neutropenia were deemed unevaluable, although comparison of hematologic and clinical indices (including infection rates) for this group with those for the analyzed cohort revealed no significant differences (data not shown). For the 71 subjects included in the natural history analysis, the median time between repeated ANCs was 9 days (range, 1-38 days; including 14 episodes that lasted у30 days); days) with nonspecific symptoms of malaise and lethargy. Twelve subjects (17%; including the 4 with culture-proven severe infection, 1 with chest infection, and 1 with a large axillary abscess) were classified as having infections during an episode of neutropenia, although a causative organism was isolated only in 6 cases (8%) and only 4 were considered serious, resulting in admission to the hospital (table 2) . None of the episodes were fatal. Prolonged neutropenia was only rarely complicated by infection ( figure 1) ; most of the infections occurred early in the episode of neutropenia and were associated with a rebound in the WBC count. Those 
DISCUSSION
This prospective study demonstrates that although moderate reductions in neutrophil count are common in HIV infection, these are rarely severe and are rarely associated with infection. Most episodes of neutropenia were associated with concomitant potentially myelosuppressive drug therapy, supporting the findings of a recent French study in which discontinuation of drug therapy was usually associated with a sharp rebound in the neutrophil count [8] . Our study, in which therapies were continued, shows that such a policy is probably not necessary, as has been suggested previously [9] , although discontinuation of drug therapy or dose reduction in the French study did allow a clearer relationship between the drugs and potential myelosuppression to be established. The other causes of neutropenia in HIV infection include the presence of opportunistic infections or malignancies affecting bone marrow function, which was rare in this cohort, and the possible presence of HIV-related myelodysplasia. Early identification of an inhibitor of in vitro granulopoiesis in sera of subjects with AIDS [10] suggested that autoimmunity may play a part in neutropenia in HIV infection; however, further studies showed that the presence of neutrophil-bound Ig correlated with disease stage but not with neutropenia [2, 11] . In previous highly selective studies, myelodysplasia appears to have been a common accompaniment of advanced HIV disease [12, 13] and was likely present in many of our patients, both those who became neutropenic and those who did not. Although it is difficult to attribute the fluctuations in ANC to fluctuations in the degree of HIV-mediated myelodysplasia, it seems likely that the presence of myelodysplasia renders individuals more susceptible to myelosuppressive therapies. The considerably lower CD4 ϩ cell counts in those patients who became neutropenic than in those with normal ANCs might imply that HIV myelosuppression becomes more pronounced as HIV disease progresses, which is supported by the extremely low rates of neutropenia among patients with higher CD4 ϩ cell counts who were being treated with the same drugs.
There are inherent problems in studies such as this investigation, partly because ANC is a continuous variable but (for logistical reasons and to aid comparison between studies) neutropenia is treated as a dichotomous variable; you either are or are not neutropenic. Unavoidably, several of the patients in our study received G-CSF treatment, which has proven efficacy in augmenting the neutrophil count in neutropenic patients with HIV infection [14] . If we had chosen to exclude these patients from our analysis (for receiving neutropenia-modifying therapy), then we would have omitted some of those patients most severely affected, thereby considerably underestimating the sepsis rate. It should be recognized that G-CSF has other immunomodulatory effects independent of the augmentation of neutrophil count; thus, the use of G-CSF in this study may have also affected the infection rate through such mechanisms. Although the inclusion of these subjects serves to underestimate the mean duration of neutropenic episodes, this effect is unlikely to be considerable. The prospective study design allowed us to closely define the course of most episodes of neutropenia; in addition, vigilant follow-up ensured that no infections were overlooked. By determining ANCs frequently, we minimized overestimation of neutropenia duration and underestimation of ANC nadir.
Although neutropenia is clearly associated with an increased risk of bacterial sepsis in the setting of hematologic malignancy [5] , there was some delay before the intuitive association between neutropenia and bacterial sepsis in HIV-infected subjects was established [15, 16] since earlier studies failed to demonstrate a correlation [17] . We noted in a retrospective study that neutropenia occurs frequently in subjects with HIV infection but is associated with a surprisingly low complication rate [7] ; moreover, neutropenia contributes to !15% of episodes of bacterial sepsis in our unit [6] . It is widely thought that the low rate of neutropenia-related sepsis may be related to the rarity of severe neutropenia in HIV infection, which is certainly borne out in this study with only 3 patients with ANC nadirs of !200 cells/mm 3 . The duration of neutropenia was, in general, short and was certainly no longer in those individuals who developed sepsis; however, their CD4 ϩ cell counts were lower, and it may be that subtle interplays between the progressive cellular immune deficiency of HIV disease and neutropenia are important in the development of infection. Although efficacy is unquestioned, the role of G-CSF and granulocyte-macrophage-CSF in the correction of neutropenia in HIV infection remains unclear. Endogenous G-CSF levels are lower in afebrile neutropenic HIV-infected subjects than in afebrile patients with acute myeloid leukemia and chemotherapy-induced neutropenia, but these levels respond with appropriate increases during acute febrile infection [18] . Ten patients received G-CSF treatment in our study, of whom 6 had evidence of infection. It might seem a reasonable policy to reserve recombinant G-CSF therapy for those patients with severe neutropenia and for those who, in the presence of more modest neutropenia, have developed sepsis. An observational strategy may be the optimal management in the absence of sepsis [19] with or without protease inhibitor therapy, which has been shown to increase ANCs in the long term [20] . It is likely that the risks of bacterial sepsis particularly in the later stages of HIV disease are related not only to neutropenia and CD4 ϩ lymphopenia but also to abnormalities of neutrophil function, particularly chemotaxis [21] , which have been attributed to disordered expression of neutrophil adhesion molecules [22] . Recent advances in the analysis of neutrophil dynamics through measurement of sCD16 in plasma may yet reveal neutrophil turnover to be a far superior indicator of susceptibility to infection than the absolute number of circulating neutrophils [23] .
